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Summary The burden and aetiology of type 2 diabetes (T2D) and its microvascular complications may be inﬂuenced by
varying behavioural and lifestyle environments as well as by genetic susceptibility. These aspects of the epidemiology of
T2D have not been reliably clariﬁed in sub-Saharan Africa (SSA), highlighting the need for context-speciﬁc
† These authors contributed equally to this work.
* Address for correspondence: Prof A.A. Motala, Department of Diabetes and Endocrinology, School of Medicine, University of KwaZulu-Natal, Private Bag 7,
Congella, 4013, South Africa.
(Email: motala@ukzn.ac.za)
Dr M. Sandhu, Department of Medicine, International Health Research Group, University of Cambridge, Cambridge, UK.
(Email: ms23@sanger.ac.uk)
Prof C. Rotimi, Center for Research on Genomics and Global Health, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD,
USA.
(Email: rotimic@mail.nih.gov)
© The Author(s) 2016. This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, pro-
vided the original work is properly cited.
global health, epidemiology and genomics
https://www.cambridge.org/core/terms. https://doi.org/10.1017/gheg.2015.6
Downloaded from https://www.cambridge.org/core. London School of Hygiene & Tropical Medicine, on 15 Jan 2018 at 16:27:37, subject to the Cambridge Core terms of use, available at
epidemiological studies with the statistical resolution to inform potential preventative and therapeutic strategies.
Therefore, as part of the Human Heredity and Health in Africa (H3Africa) initiative, we designed a multi-site study com-
prising case collections and population-based surveys at 11 sites in eight countries across SSA. The goal is to recruit up to
6000 T2D participants and 6000 control participants. We will collect questionnaire data, biophysical measurements and
biological samples for chronic disease traits, risk factors and genetic data on all study participants. Through integrating
epidemiological and genomic techniques, the study provides a framework for assessing the burden, spectrum and
environmental and genetic risk factors for T2D and its complications across SSA. With established mechanisms for ﬁeld-
work, data and sample collection and management, data-sharing and consent for re-approaching participants, the study
will be a resource for future research studies, including longitudinal studies, prospective case ascertainment of incident
disease and interventional studies.
Received 29 September 2015; Revised 20 November 2015; Accepted 25 December 2015
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Background
Type 2 diabetes (T2D) is a major cause of premature mor-
tality and morbidity worldwide. In sub-Saharan Africa (SSA),
T2D is an emerging epidemic with a current prevalence of
around 1–6% [1]. In this region, it is estimated that 22 mil-
lion adults were living with diabetes in 2013; this ﬁgure is
expected to be more than double by 2035, representing
the largest proportional increase in the burden of diabetes
of any region in the world [2, 3]. The disorder presents a
major health problem in SSA, competing for limited health
resources with infectious diseases and other emerging non-
communicable diseases (NCDs) such as cardiovascular dis-
ease [1, 4–7].
Although, several established and emerging risk factors for
T2D and cardiovascular diseases in Africa are similar to those
found in other parts of the world, the magnitude and distri-
bution of these factors may differ, and have not been fully
studied in SSA in a large-scale epidemiological context [4].
Population growth and the concomitant rise in life expect-
ancy only partly explain the increase in diabetes and other
chronic diseases. Many of the known risk factors for NCDs
in high-income countries are the same for low- and middle-
income countries, including smoking, alcohol and obesity;
however, there is an additional impact of rapid urbanisation
and globalisation and the associated trends towards unhealthy
lifestyles. Additionally, the role of endemic infections on the
aetiology of T2D, as well as on the prevalence and spectrum
of diabetic complications has not been clariﬁed in SSA [6].
In addition to these environmental and lifestyle risk fac-
tors, genetic predisposition towards T2D may provide ad-
ditional insights into the differences in T2D prevalence
observed between populations in SSA. At present, there
are around 100 loci for which there is robust (genome-wide
signiﬁcant) evidence of association with traits related to
T2D, including obesity and fasting hyperglycaemia, identiﬁed
in predominantly European and Asian populations.
However, the relevance of many recent genomic ﬁndings
to populations in SSA has not been systematically studied.
Given the marked genomic diversity among populations in
SSA, understanding the genomic basis of T2D, its
complications, and its risk factors in populations of African
descent is likely to provide additional insights into disease
aetiology and potential therapeutic strategies [8, 9]. These
observations highlight the need for epidemiological studies
with the statistical resolution to reliably assess the burden
and epidemiology of T2D and inform potential preventative
and therapeutic strategies relevant to SSA.
Therefore, we have designed a multi-country study com-
prising 11 study sites located across eight countries in SSA
to investigate the epidemiology and aetiology of T2D
(Fig. 1 and Table 1). Each participating study site will collect
cases of participants with T2D drawn from hospital clinics
and healthcare facilities, and conduct a cross-sectional
population-based survey to recruit controls. In total, across
all study sites, we aim to recruit approximately 6000 cases of
T2D and 6000 controls. Using harmonised and standardised
tools for recruitment and data collection, we will be able to
estimate the prevalence of T2D across SSA and conduct
region-wide pooled analyses using comparable data, in
order to identify risk factors and their relative contribution
to T2D. This study will thus create a large-scale epidemiolo-
gical and genomic research framework for improving our
understanding of the burden and risk factors for diabetes,
which may inform health service planning and prevention
strategies across Africa. The study will also provide insights
into the molecular and pathophysiological basis of diabetes
in African populations and hence contribute to medical
genomics efforts globally.
Study aims and objectives
The overarching aim of the study is to assess the burden and
aetiological characteristics of T2D in adults in SSA, using
large-scale population-based approaches. Within this aim,
we have two study objectives:
(1) To assess the burden, spectrum and environmental and
genetic determinants of T2D among adults in SSA. This
aim will be addressed across all 11 study sites.
(2) To characterise the prevalence, distribution and en-
vironmental and genetic determinants of microvascular
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complications of diabetes among adults with T2D in
SSA. To address this aim, nephropathy will be assessed
across all 11 study sites. Diabetic retinopathy will be
assessed in a sub-set of four study sites (Blantyre,
Malawi; Abuja, Nigeria; Cape Town, South Africa; and
Durban, South Africa).
Methods
Study sampling frame
Each study site will generate a geographical sampling frame
for the case collection and population-based survey. First,
using residency records from diabetes registers in hospital
clinics and healthcare facilities, each site will generate a list
of the diabetes patients seen in the preceding 12 months
and the geographical location or administrative region
they come from. Using this information, a list will be cre-
ated of the speciﬁc locations from where the majority of
patients originate, to provide a geographical sampling
frame for recruitment of cases and controls into the
study (Figs 2 and 3).
Deﬁnitions
Clinically diagnosed T2D cases, based on data from patient
medical records, will be deﬁned according to current
American Diabetes Association and World Health
Organization (WHO) deﬁnitions [10, 11]: fasting plasma glu-
cose (FPG) ≥7.0 mM/ (≥126 mg/dl) or 2-h post-load plasma
Fig. 1. Geographical distribution of study sites in the H3Africa type 2 diabetes study.
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glucose (2 h-PG) ≥11.1 mM/l (≥200 mg/dl) during oral glu-
cose tolerance test (OGTT) or symptoms of diabetes and
random plasma glucose ≥11.1 mM/l (≥200 mg/dl) or on
treatment for diabetes (based on medical records or self-
report). HbA1c will not be used to deﬁne diabetes in this
study because its use has not been validated in this popu-
lation, although it will be measured for comparison with
glucose-based criteria. Presence or absence of diabetic reti-
nopathy will be assessed according to the Liverpool Diabetic
Eye Study grading for both retinopathy and macular
Table 1. Coordinating institutions and research partners for the H3Africa T2D study. The study comprises 11 sites in SSA, where ﬁeld work is
undertaken, together with research partners from the UK and the USA
Country Coordinating institution
Field study sites
Cameroon Health of Populations in Transition, University of Yaoundé 1
The Gambia MRC Keneba, MRC Unit, The Gambia and University of The Gambia
Guinea CHU Donka, University of Conakry, Non Communicable Disease Unit, Ministry of Health
Malawi Malawi‐Liverpool-Wellcome Trust Unit, Blantyre
Nigeria University of Nigeria Teaching Hospital, Enugu
Nigeria Institute of Human Virology, Abuja
South Africa Faculty of Health Sciences, University of Cape Town
South Africa Nelson R Mandela School of Medicine, University of KwaZulu‐Natal, Durbana
Tanzania National Institute for Medical Research, Dares Salaam, Hindu Mandal Hospital, Muhimbili University of Health and Allied
Sciences, Muhimbili National Hospital, and Nelson Mandela Institute
Tanzania Mwanza Intervention Trials Unit/NIMR Tanzania
Uganda MRC/UVRI Uganda Research Unit on AIDS, Entebbe
Research partners
UK Cambridge University; Wellcome Trust Sanger Institute; MRC Epidemiology Unit, Cambridge
UK London School of Hygiene and Tropical Medicine
UK Wellcome Trust Centre for Human Genetics; MRC Centre for Global Health Genomics, Oxford University
USA National Human Genome Centre, Howard University, Washington; National Human Genome Research Institute,
National Institutes of Health; Case Western Reserve University
a The principal investigator for the study – Prof Ayesha Motala – is based at this study site.
Fig. 2. Schematic of multi-country case collection and cross-sectional survey design.
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exudates [12]. Microalbuminuria will be deﬁned as
albumin-to-creatinine ratio >2.0 mg/mM [13]. These case
deﬁnitions will be used across all study sites to ensure con-
sistency and comparability of data.
Recruitment of T2D cases
In each study site, cases of T2D who live in the study geo-
graphical sampling frame will be recruited from hospital
clinics and healthcare facilities using predeﬁned inclusion
and exclusion criteria (Table 2). Patients with T2D will be
identiﬁed from patient registers and their clinical details
entered into a case review dataset, to be assessed for eligi-
bility before being invited to participate in the study.
Eligibility will be independently monitored by senior clinicians
from two of the collaborating institutes, who will receive and
review the case review datasets from each study site to en-
sure that inclusion and exclusion criteria – in particular, diag-
nostic criteria for T2D – are applied consistently across all
study sites. Individuals who agree to participate in the study
will be required to provide written informed consent before
recruitment (online Supplementary Appendix 1a); at study
sites participating in the retinopathy sub-study, individuals
will additionally consent to undergo digital fundus photogra-
phy to assess and characterise the presence and severity of
diabetic eye disease (online Supplementary Appendix 1b).
Recruitment of population-based controls
In parallel to case recruitment, each study site will conduct a
population-based cross-sectional survey to recruit controls
within the geographical sampling frame to ensure the cases
and controls are recruited from the same geographical re-
gion. Using standardised procedures across all sites, the sur-
veys will adopt a multi-stage sampling design: the primary
sampling units (clusters) are administrative units that are
selected with probability proportional to size, and house-
holds are the secondary units selected by simple random
sampling. Next, based on predeﬁned inclusion and exclusion
criteria (Table 2), eligible adults from the selected house-
holds will be invited to participate in the study. For the
population-based surveys we will opt to use minimal in-
clusion/exclusion criteria in order to obtain a broadly rep-
resentative sample of the population. This approach will
allow the opportunity to align controls to other cases that
could potentially be collected in the context of future pro-
posals focusing on other diseases and traits.
Individuals, who wish to take part will be invited to attend
static or mobile clinical hubs after an overnight fast of at
least 8 h, and will be asked to provide written informed con-
sent (online Supplementary Appendix 1c). As described
later, the diabetes status of all survey participants (regardless
of any self-reported medical history of T2D) will be estab-
lished by undergoing a 75 g OGTT. Based on these OGTT
results, participants without T2D will be used as controls
for the study, while those found to have T2D will be
added to the cases at analysis.
Sample size and statistical power
A total of just over 12 000 participants will be recruited
across all sites (with a minimum of 400–800 cases and an
equal number of controls per site). In practice, at each
study site the number of survey participants will be over-
sampled by around 10%, in order to obtain a number of con-
trols equal to the number of cases based on an estimated
prevalence of T2D of 10% among adults in the survey.
Thus, the total survey sample size across all sites will be
about 7000 participants. The sample size for the diabetic
retinopathy sub-study will be approximately 2000 indivi-
duals. Other complications, namely microalbuminuria will
be assessed among T2D cases across all sites, and will
have a sample size of 6000.
With a survey sample size of 7000 we will estimate the
prevalence of T2D with high precision. For example, given
a true prevalence of 10% and design effect (deff) of 3 or
4, we will estimate prevalence in the survey to within
±1.2% or ±1.4%, respectively. The precision will be greater
with lower deffs: precision will be within ±0.7, ±0.9 and
±1.0% for deffs equal to 1, 1.5 and 2, respectively. Risk fac-
tors for T2D will be assessed using logistic regression based
on 6000 cases and 6000 controls. The study will have more
than 80% power of detecting odds ratios (ORs) as low as
1.5. Any loss of statistical power due to clustering of indivi-
duals within households is insigniﬁcant, as demonstrated by
the near coincidence of power-effect size graphs with and
without adjustment for clustering (Fig. 4).
Fig. 3. Generating a geographical sampling frame at each site.
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Data collection
Using the standardised procedures across all sites, we will col-
lect detailed information from all study participants (T2D cases
and survey participants) on health, lifestyle, medical and socio-
economic indices, as well as biophysical measurements, bio-
sample collections for markers of non-communicable and
infectious diseases, and genetic information. To maximise ef-
ﬁciency and convenience for participants, all data and samples
are collected in a single study visit. Details of data and sample
collection are shown in Tables 3 and 4. Questionnaire data will
be collected using an electronic data capture system [elec-
tronic questionnaire (EQ)] developed by the African
Partnership for Chronic Disease Research (APCDR) (http://
www.apcdr.org/). To increase accuracy and efﬁciency of data
collection, the EQ has built-in data checks, including double
entry of numbers, plausibility of answers and appropriate nu-
merical limitations, which have been described in detail else-
where [14]. The EQ is administered through face-to-face
interview and is based on the standardised and validated
WHO STEPwise approach to Surveillance (STEPS) tool
designed for the collection of chronic disease risk factors
[15]. The questionnaire is available on request.
A range of biophysical measurements are taken (Table 3)
with calibrated and validated equipment, using standardised
procedures to ensure consistency and harmonisation of
data across study sites. These data are also collected as
part of the EQ dataset. Additionally, for T2D cases in the
diabetic retinopathy sub-study, digital fundus photography
will be used to assess the presence and severity of diabetic
retinopathy and maculopathy. Photographic images will be
graded at a central retinopathy hub in Durban, South
Africa, using the Liverpool Diabetic Eye Study protocol.
Venous blood and untimed spot urine samples will be col-
lected from all T2D cases and survey participants after a
preceding overnight fast of 8–12 h (Table 4). Further, all sur-
vey participants (including those with self-reported diabetes)
will have a fasting ﬁnger prick blood glucose test and also
undergo an OGTT (regardless of ﬁnger prick glucose re-
sult), requiring additional blood samples to be taken 2 h
after the 75 g oral glucose load. Blood and urine samples
will be stored in cold boxes maintained at 4–8 °C using stan-
dardised procedures, until transported to a laboratory on
the same day as sample collection.
Sample processing, biobanking and management
At each study site, blood and urine samples will be trans-
ported from the ﬁeld to the local laboratory for further pro-
cessing and analysis or storage, full details of which are
available on request. In brief, full blood count is measured
at the local laboratories, on the day of sample collection.
Table 2. Inclusion and exclusion criteria for cases of T2D and population-based controls
Inclusion criteria Exclusion criteria
Case of T2D
• Age ≥25 years
• Clinically diagnosed T2Da
• Individual of African origin
(Black)
• Signed informed consent
• Pregnant womenb
• Diabetes classiﬁed other than T2D or doubt as to classiﬁcation
• Resident outside the geographical sampling frame for the relevant study
site
• Self-deﬁned ethnic group regarded as other than African (Black)
• Unable to give informed consent
Population-based
controls
• Age ≥18 years
• Individual of African origin
(Black)
• Signed informed consent
• Pregnant womenb
• Resident outside the geographical sampling frame for the relevant study
site
• Self-deﬁned ethnic group regarded as other than African (Black)
• Unable to give informed consent
T2D, type 2 diabetes.
a T2D deﬁned according to current World Health Organization and American Diabetes Association guidelines – see methods section.
bWomen can participate in the study from six months after childbirth. The minimum age for participation in the population survey
has been set at 18 to obtain a broadly representative sample of the underlying adult population. This will allow the opportunity to align
controls to other case series that could potentially be collected in the context of future studies of other diseases and traits.
Fig. 4. Power for a range of odds ratios and prevalence of
exposure, with and without adjustment for clustering.
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The ethylenediaminetetraacetic acid (EDTA) whole blood
samples (5 or 6 ml) for genomic analyses will be transferred
to cryotubes for storage at −80 °C, before being shipped to
the central biorepository in Uganda for the subsequent DNA
extraction and next-generation genotyping and sequencing.
Using standardised procedures, all other samples will be pro-
cessed at the local laboratories for storage, including centri-
fugation, separation into serum and plasma and aliquoting
into linked-anonymised barcoded microvials. Derived from
each original collection tube, a set of microvials is sent to
the central biorepository, whilst ensuring that back-up micro-
vials are banked at the local laboratory indeﬁnitely.
Apart from full blood count, all other laboratory tests and
analyses will be conducted at the central biorepository
which is located at the Medical Research Council/Uganda
Virus Research Institute in Entebbe, Uganda. Samples are
shipped to the central biorepository on dry ice, and are stored
at −80 °C immediately on arrival. When sufﬁcient numbers of
samples have been received from different sites, batches of
samples are selected, thawed and tested following standardised
procedures (Table 4). For each assay run, samples from a
number of different sites will be selected for testing in order
to reduce bias in the biomarker measurements. Therefore,
biochemical assays will be done randomly with respect to
study site and case/control status. Samples for each participant
will also be banked at the central biorepository as a resource
for future research. Access to banked samples will follow stan-
dardised procedures and will be governed by the Biospecimen
and Data Access policies of Human Heredity and Health in
Africa (H3Africa) consortium (h3africa.org).
Table 3. Data collection components in the H3A T2D study
All participants
Demographic
• Age
• Sex
• Marital status
• Ethno-linguistic group
• Migration history
Participant medical history • Hypertension, dyslipidaemia, coronary heart disease
• Stroke, renal disease, diabetes-related eye disease
• HIV status, TB, malaria and other chronic infections (such as HCV), ART use
Lifestyle • Diet, physical activity, exercise
• Smoking, alcohol consumption
Socioeconomic • Level of education
• Years spent in school
• Household size
• Household income
• Occupation
Biophysical measurements • Height, weight
• Waist circumference, hip circumference
• Blood pressure
First degree family history • Diabetes, hypertension, dyslipidaemia, coronary heart disease
Survey participants only:
Participant medical history • T2D
T2D cases and survey participants with self-reported T2D:
Participant medical historya • Date of diagnosis of T2D
• Age at diagnosis of T2D
• Current therapy for diabetes
• Date of commencement of insulin therapy (if applicable)
• Self-reported presence of known microvascular complications
ART, antiretroviral therapy; HCV, hepatitis C virus infection; T2D, type 2 diabetes; TB, tuberculosis..
a For cases, these data are obtained from medical records captured in the case review form.
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DNA extraction and generation of genomic data
From each study participant, the central biorepository hub
will receive an EDTA whole blood cryotube for DNA ex-
traction. The DNA will be extracted and divided into
three samples: one for genotyping and sequencing, a second
sample to be returned to the local site, and a third sample
for biobanking at the central biorespository hub.
Generation of genomic data – including next-generation
sequencing, genotyping arrays and imputation – will be
undertaken in several established and internationally com-
petitive genome centres, such as the Wellcome Trust
Sanger Institute, UK.
Data management
Data management for the study comprises processes for
handling, storage and transfer of data at the local study
sites, and at the various central hubs for this study (biorepo-
sitory, retinopathy and bioinformatics). These processes are
outlined in Fig. 5. Study sites will perform standardised qual-
ity control checks on their datasets before sending them to
the central hub, for merging with laboratory results and reti-
nal results to create a master dataset. Genomic data will be
stored by the European Genomephenome Archive at the
European Bioinformatics Institute, Hinxton, UK and in
data centres in Africa – for example, the data centre of
the APCDR in Uganda or the H3ABioNet in Cape Town.
Curated and processed genomic data ﬁles will also be stored
and managed at the central bioinformatics hub in South
Africa. DNA may also be sent to, and stored, at other gen-
ome centres.
All these aspects of data management are described in
more detail in standardised operating procedures which
are available on request. There are also broader considera-
tions and obligations for managing and sharing data across
the wider H3Africa consortium, which are relevant to this
study but fall outside the scope of this protocol paper.
Statistical analysis plan
We will conduct site-speciﬁc analyses as well as study-wide
pooled analyses. First, for each study site, means and medians
with 95% conﬁdence intervals (CIs) and interquartile range
(IQR) will be calculated to summarise continuous risk factors.
T-tests (or non-parametric tests where appropriate) will be
used to compare results between cases and controls.
Categorical risk factors will be summarised as frequencies and
percentages with 95% CIs, and their prevalence in cases and
controls compared using χ2 tests. Age- and sex-adjusted preva-
lence of T2D (and other diseases and risk factors) will be
weighted appropriately to account for themulti-stage study de-
sign, and presented with 95% CIs [16, 17]. To determine risk
factors and their relative contribution to the risk of developing
T2D, odds of T2Dwill be modelled using logistic regression to
obtain crude and adjustedORs and 95%CIs. Foroutcomes that
do not satisfy the rare disease assumption, a Poisson regression
modelwill be used tomodel the probability of a givenmicrovas-
cular complication to obtain prevalence ratios (PRs).
Population attributable fractions (PAFs) will be estimated to as-
sess the relative contribution of each risk factor using the inter-
active risk attributable program software [18–20].
In addition to the above, we will pool site-level estimates of
prevalence, ORs, PRs and PAFs to produce SSA-wide as well
as regional (East, West and South SSA) estimates using
Table 4. Schedule of biosample collection. The list indicates the planned use for a single microvial derived from each sample collected. Remaining
microvials are banked, both at the local laboratories and at the central biorepository, for long-term storage and future testing
Sample collected Use of samples
Collected at baseline,
0 min, from all participants
(fasting)
10 ml plain serum blood tube Biochemistry, serology &
insulin and C-peptide
5 ml or 6 ml EDTA whole blood tubea DNA extraction
2 ml EDTA whole blood tube Full blood count
2 ml EDTA whole blood tube HbA1c
10 ml EDTA whole blood tube Plasma extraction for viral genomics
2 ml NaF blood tube Fasting plasma glucose
Spot urine collection Albumin-to-creatinine ratio,
urinary Na and K
Collected at 120 min
(non-fasting) from survey
participants only
4 ml plain serum blood tube Insulin and C-peptide
2 ml NaF blood tube Plasma glucose
a Volume of whole blood EDTA tube for DNA extraction will depend on local availability.
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random effects meta-analyses. A random effects model will be
used because it accounts for between-site heterogeneity
which we anticipate will be present in this study and will
allow us to generalise the ﬁndings from this study to a
wider population of similar studies [21, 22]. The type one
error rate will be adjusted to account for multiple compari-
sons [23]. All statistical tests of hypotheses will be two-sided
and signiﬁcance tests performed at the 5% level.
Fig. 5. Overview of data management processes in the H3Africa type 2 diabetes study.
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Disclosure of study results to participants
Study participants will be given their body mass index and
blood pressure measurements in the ﬁeld, at the point of
data collection; survey participants will also receive their
ﬁnger-prick blood glucose results. Where these results
are abnormal, participants will be referred to their local
clinic or hospital. Receipt of blood results is optional for
participants, and individuals with abnormal venous blood
results will be referred to their local clinic or hospital.
Given the clinical implications of genetic proﬁles are un-
known at the population and individual level, individual gen-
etic data will not be disclosed to participants. This decision
may be revisited in the future as the scientiﬁc community
gains more insight into the practical clinical implications
of genetic proﬁles of individuals. Aggregate genomic data
will be disclosed to participants through meetings and
seminars for study participants and local stakeholders
in line with H3Africa public engagement policies and fol-
lowing site-speciﬁc procedures.
Study governance
The study is led by the study principal investigator (PI –
Professor A. A. Motala) and a scientiﬁc steering committee
(SSC)1. The SSC comprises all local study site PIs and asso-
ciated research partners. The study PI and SSC together are
the custodians of the study, including samples and data, and
are responsible for making critical decisions about the re-
search direction of the programme. The study PI and SSC
have complete autonomy with respect to dissemination,
publication and scientiﬁc collaboration with the data and
samples of the study. Advisory support and oversight will
be provided by H3Africa governance structures.
Ethical considerations
This protocol has undergone ethical review and received ap-
proval from institutional review boards and relevant national
regulatory bodies at each of the participating study sites.
Where required in order to obtain such approval, details of
the protocol have been amended to satisfy local conditions,
but without affecting the scientiﬁc integrity of the overall
study. To further ensure that the study conduct is harmo-
nised across the study sites, all aspects of the study – from
generating the sampling frame, through to case identiﬁcation,
participant recruitment, data and sample collection and sub-
sequent data management and sample processing – are
detailed in standardised procedures; these are available on
request.
Written informed consent is obtained from all study par-
ticipants. The consent form covers the following activities:
data collection by questionnaire and biophysical measures,
sample collection and analysis including feedback of selected
results, consent for DNA extraction and genomic analyses,
consent for use of data and samples for future research,
data deposition and sharing with H3Africa investigators
and the wider scientiﬁc community via a process of managed
access, and permission to re-approach participants for new
studies.
Discussion
This is a multi-site, multi-country population-based study
integrating epidemiology and population genetics
approaches to better understand the aetiology of T2D in
SSA. A strength of this study is its broad geographical cover-
age and sample size. The study draws participants from
West, East and Southern Africa, which enhances the rel-
evance of its ﬁndings to populations across SSA. Secondly,
with 6000 cases and 6000 controls, it will be the largest
study of the epidemiology of T2D in SSA to date. This stat-
istical resolution presents opportunity for uncovering new
associations and risk factors. The study will include data on
a broad range of exposures and phenotypes including chronic
non-communicable and infectious diseases and risk factors,
thus having the potential to address a wide-ranging set of re-
search questions and the ability to provide biological insights
into the variation in risk factors for a range of chronic dis-
eases among adults in SSA. By aligning these data to genomic
data, the study will be a platform for investigating genetic
determinants of T2D and its complications. With a strong
commitment to developing local research capacity, the
study also provides opportunities for strengthening research
infrastructure and analytical expertise for large-scale genomic
and epidemiological studies across SSA [24].
A limitation of this study is its cross-sectional nature which
means we will not be able to establish the temporal relation-
ship between risk factors and outcomes. However, we plan
to obtain consent from participants to re-approach them in
the future, with the potential for establishing follow-up stu-
dies, prospective studies of disease incidence, and creating
a platform for future research including studies of diabetes
complications, interventional studies and clinical trials.
Furthermore, the study has been designed speciﬁcally to
allow for a broader use of population survey participants
as control sets for many other disease case collections in
the context of future studies. Banked biosamples are also
available for future analyses. The study has no upper age
limit for participants and is therefore well placed to investi-
gate disease and risk factors in older populations. The
study represents a diverse set of populations and environ-
ments. This design may lead to heterogeneity in the relation-
ship between exposures and T2D risk. However, a key
strength of this study is its use of agreed case deﬁnitions
and standardised operating procedures across all study
sites. With this level of harmonisation, the study will permit
between-country and regional comparisons of disease bur-
den and risk, and exploration of heterogeneity which may
give deeper insight into contextual factors underlying disease
aetiology.
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Importantly, in a wider context, the study is well posi-
tioned for large-scale collaborative research – for example,
it is part of the H3Africa consortium which has purposefully
harmonised the assessment of phenotypes across its pro-
jects within this pan-Africa framework. In this way, the
study represents a rich resource for providing evidence on
the burden of T2D and other chronic diseases to inform
the development of prevention and treatment strategies in
the region. Further, the central aim of the study is to inte-
grate epidemiological methods with population genomics
and next-generation technologies. This approach has already
provided new insights into the biology of chronic diseases
and their risk factors in Western populations [9].
However, the relevance of many recent genomic ﬁndings
to populations in SSA is not known. To date, genome-wide
association studies in Africa have been limited to just a few
thousand individuals across a limited number of cardiometa-
bolic or infectious diseases and traits. Representing a major
shift in the size of such studies, we aim to integrate genomic
analyses into the proposed study, as well as to align such
efforts with the wider H3Africa consortium. Given the
marked genomic diversity among populations in SSA, under-
standing the genomic basis for chronic diseases and their
risk factors in populations of African descent is likely to pro-
vide additional insights into the genetic determinants of
chronic diseases and potential therapeutic strategies, includ-
ing opportunities to discover novel disease susceptibility loci
and variants and to reﬁne (ﬁne-map) association signals at
new and existing disease and trait loci [25, 26]. The study
is thus designed to maximise these opportunities for con-
ducting large-scale genomic analyses and participating in
genomics research globally.
Collaboration and data sharing
In publishing this study protocol, the study investigators aim
to maximise the scientiﬁc potential of this study, and wel-
come the fullest possible use of the data internationally.
Data will be available to bona ﬁde researchers and analysts
who fulﬁl eligibility criteria, through a process of managed
access. The study investigators also wish to encourage colla-
borations with other research institutes, stakeholders and
policymakers. All data enquires should be made to the over-
all PI, Prof. Ayesha Motala (motala@ukzn.ac.za). Study docu-
mentation (protocol, participant information sheets and
consent forms, questionnaires and standardised operating
procedures) will be available via the APCDR website
(data@apcdr.org).
Note
1. Lead investigators from each collaborating institution –
C. Adebamowo, N. Balde, B. Hennig, P. Kaleebu, S. Kapiga,
N. Levitt, M. Mayige, J. C. Mbanya, M. McCarthy, A. Motala,
O. Nyan, M. Nyirenda, J. Oli, C. Rotimi, M. Sandhu, E. Sobngwi.
Supplementary material
To view supplementary material for this article, please visit
http://dx.doi.org/10.1017/gheg.2015.6
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